SMC say “no” to Kyprolis® and Darzalex® for myeloma patients in Scotland
Scotland's drug approval body has decided not to recommend both Kyprolis® (carfilzomib) and Darzalax® (daratumumab) for myeloma patients.
Myeloma UK made a strong case to the SMC and we are very disappointed by the decision.
Scotland's drug approval body has decided not to recommend both Kyprolis® (carfilzomib) and Darzalax® (daratumumab) for myeloma patients.
Myeloma UK made a strong case to the SMC and we are very disappointed by the decision.
